OmniAb names Amechi Nwachuku as chief operating officer

OmniAb, Inc. (NASDAQ: OABI) has appointed Amechi Nwachuku to the newly created position of Executive Vice President and Chief Operating Officer, according to a company press release.

Nwachuku will be primarily responsible for managing the strategy, operations and commercial development of xPloration, OmniAb's single B-cell screening platform.

Nwachuku brings more than 25 years of experience in life sciences. He most recently served as Vice President of Global Commercial Genetic Sciences at Thermo Fisher Scientific, and previously as Senior Vice President of Global Commercial at SCIEX, a Danaher Corporation unit. He also held senior roles at Beckman Coulter Diagnostics, Johnson & Johnson Diabetes Care and Bayer, and began his career as a management consultant at McKinsey & Company. He holds a Bachelor of Science in Chemical Engineering and an MBA from the Massachusetts Institute of Technology.

Matt Foehr, President and Chief Executive Officer of OmniAb, said in the statement: "Throughout his career, Amechi has established a proven track record of commercial and operational excellence, consistently driving growth, capitalizing on market opportunities, and efficiently creating value."

OmniAb licenses antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The company's business model includes upfront fees, service revenue, milestones and royalties on commercial sales.

You May Also Be Interested In

• Calix names Juergen Lindner as chief marketing officer
• Polaryx Therapeutics names Will Charlton as chief medical officer
• Energy Vault’s 100 MW AI Infrastructure Project in Sardinia Receives Italian Government Designation as Project of Pre-Eminent National Strategic Interest